Exchange: NASDAQ·Updated 07:50 PM EDT

MRKR News

News
all
press releases
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
MARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
MARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
More News
New Strong Buy Stocks for October 16th
UGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.
Zacks
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Zacks
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Zacks
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -85.71% and +7.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of 0.00% and -21.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.